Detalhe da pesquisa
1.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Haematologica
; 107(3): 774-775, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35229573
2.
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Haematologica
; 106(4): 1182-1187, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586908
3.
A retrospective study of morbidity and mortality of chronic acid sphingomyelinase deficiency in Germany.
Orphanet J Rare Dis
; 19(1): 161, 2024 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38615062
4.
Survival of patients with chronic acid sphingomyelinase deficiency (ASMD) in the United States: A retrospective chart review study.
Mol Genet Metab Rep
; 38: 101040, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38188692
5.
Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
Diabetes Technol Ther
; 23(1): 70-77, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32721228
6.
Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
J Rheumatol
; 46(10): 1259-1267, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30877216
7.
Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
Arthritis Res Ther
; 20(1): 129, 2018 06 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29921318
8.
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
RMD Open
; 3(1): e000416, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28326189
9.
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma.
J Allergy Clin Immunol Pract
; 7(7): 2447-2449.e2, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30928658